Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
7
Neutral
4
Bullish
3
Bearish
7
Neutral
4
Bullish
35
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stock
Mankind Pharma Limited is a leading Indian pharmaceutical company engaged in manufacturing and marketing a broad spectrum of pharmaceutical products and healthcare solutions. The company operates in both acute and chronic therapeutic areas, with a notable presence in cardiovascular, anti-diabetic, and neuro/CNS segments.
In Q3 FY26, Mankind Pharma reported a revenue increase of 11.5% YoY, driven by strong domestic pharmaceutical performance. Adjusted EBITDA margins improved to 25.9%, showcasing robust operational efficiency.
The expansion into specialty and super specialty segments via BSV acquisition has marked significant growth, with BSV now contributing substantially to Mankind's revenue and offering a high entry barrier to competitors.
Mankind Pharma's consumer healthcare segment showed resilience with a 5.2% growth in Q3 FY26, bolstered by high-performing brands like Gas-O-Fast and Manforce, and increasing contributions from e-commerce and modern trade channels.
Strategic transformations in workforce and operational strategies have bolstered Mankind's foundation, positioning it for sustainable long-term growth and enhanced market position across its pharma and consumer healthcare segments.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,02,964 Cr
Low Risk
53.8
35.0
1.6
6.7
2,726.75
1,909.90
Sales CAGR
Profit CAGR
ROE
ROCE
Mankind Pharma Ltd (MANKIND) is currently trading at 2,583.35 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Mankind Pharma Limited is a leading Indian pharmaceutical company engaged in manufacturing and marketing a broad spectrum of pharmaceutical products and healthcare solutions. The company operates in both acute and chronic therapeutic areas, with a notable presence in cardiovascular, anti-diabetic, and neuro/CNS segments. In Q3 FY26, Mankind Pharma reported a revenue increase of 11.5% YoY, driven by strong domestic pharmaceutical performance. Adjusted EBITDA margins improved to 25.9%, showcasing robust operational efficiency. The expansion into specialty and super specialty segments via BSV acquisition has marked significant growth, with BSV now contributing substantially to Mankind's revenue and offering a high entry barrier to competitors. Mankind Pharma's consumer healthcare segment showed resilience with a 5.2% growth in Q3 FY26, bolstered by high-performing brands like Gas-O-Fast and Manforce, and increasing contributions from e-commerce and modern trade channels. Strategic transformations in workforce and operational strategies have bolstered Mankind's foundation, positioning it for sustainable long-term growth and enhanced market position across its pharma and consumer healthcare segments.
Over the past 52 weeks, Mankind Pharma Ltd has traded between a low of ₹1,909.90 and a high of ₹2,726.75. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Mankind Pharma Ltd has a market capitalization of approximately 1,02,963.51. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Mankind Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 53.83 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,02,963.51 Cr, Mankind Pharma Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Mankind Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Mankind Pharma Ltd is 53.83. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Revenue from operations rose 11.8% YoY to INR 3,443 crore, while PAT increased 30.4% YoY to INR 559 crore in Q4 FY26.
Mankind Pharma reported revenue from operations of INR 3,697 crore in Q2FY26, a 20.8% increase year-on-year.
The upcoming earnings date in the provided data is 19 May 2026 (listed as Q4 FY26-27).
Revenue was reported at ₹3,079.4 crore in Q4 FY25, up 27.1% year-on-year.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1361.00 | 1,13,884 Cr | 29.36 | 3.31 | 0.92 | 11.27 | 14.95 | 9.11 | ||
1307.00 | 1,11,339 Cr | 26.53 | 2.94 | 0.60 | 11.07 | 12.54 | 7.15 | ||
2326.80 | 1,04,542 Cr | 19.60 | 4.66 | 0.79 | 23.76 | 24.88 | 13.96 | ||
2507.00 | 1,02,964 Cr | 57.87 | 6.74 | 0.00 | 11.45 | 12.34 | 6.26 | ||
864.25 | 1,02,530 Cr | 20.76 | 4.05 | 0.10 | 19.44 | 19.08 | 10.52 | ||
1415.00 | 87,861 Cr | 25.20 | 2.51 | 0.00 | 9.77 | 12.69 | 6.63 | ||
1129.60 | 72,611 Cr | 81.70 | 13.70 | 0.09 | 16.77 | 16.14 | 8.47 | ||
| Median: 7 Co. | — | 1361.00 | 1,02,964 Cr | 26.53 | 4.05 | 0.10 | 11.45 | 14.95 | 8.47 |
Investor Call Recording
Mankind Pharma announced the audio recording of its Q4 & FY26 investor conference call held on May 20, 2026 is available on the company website (link provided in the filing).
Financial results publication
Mankind Pharma published newspaper advertisements of its audited financial results for the quarter and financial year ended March 31, 2026, filed under SEBI LODR (Regs. 30,47,52(8)) and published in Financial Express and Jansatta on May 20, 2026.
Earnings Release
Mankind Pharma reported Q4 FY26 revenue INR 3,443 Cr (+11.8% YoY) and FY26 revenue INR 14,278 Cr (+17%); Q4 adjusted EBITDA margin 27.1% and Q4 PAT INR 559 Cr; FY26 PAT INR 1,938 Cr with diluted FY26 EPS INR 46.3.
Earnings Release
Mankind Pharma reported Q4 FY26 consolidated revenue of INR 3,443 Cr (+11.8% YoY) and FY26 revenue of INR 14,278 Cr (+17% YoY); Q4 adjusted EBITDA margin 27.1% (FY: 25.4%); FY PAT INR 1,938 Cr; Q4 diluted EPS INR 13.4.
Earnings Presentation
Mankind Pharma reports Q4FY26 revenue of INR 3,443 Cr (+11.8% YoY) and FY26 revenue INR 14,278 Cr (+17% YoY); Q4 EBITDA INR 910 Cr (+32.7%) with adj. EBITDA margin 27.1%, Q4 PAT INR 559 Cr (+30.4%); net debt/EBITDA 1.1x.
Board Meeting Outcome
Board (May 19, 2026) approved audited standalone & consolidated results for year/quarter ended Mar 31, 2026; reappointed Satish K. Sharma as Whole‑Time Director and cost auditors; noted CIO Pramod Gokhale's resignation; approved up to ₹500cr subsidiary investment and NCD security realignment.
